Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer ...

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has ...

The ICO has fined genetic testing company 23andMe £2.31 million. It is related to a data breach that impacted the data of 155,592 UK users. The company ...

DNA firm 23andMe fined £2.31m by UK regulator for a 2023 data breach that exposed sensitive health and family information. Sale to TTAM Research to include stricter privacy commitments.

The once-popular genetic testing company is being acquired by a nonprofit led by a 23andMe co-founder, as questions persist about how to remove personal data from it.

Anne Wojcicki, founder of 23andMe, has successfully repurchased the genetic testing firm out of bankruptcy through her ...

A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

Regeneron said it would comply with 23andMe’s privacy policies and applicable law. It said it would process all customer personal data in accordance with the consents, privacy policies and ...

Hackers used a credential stuffing attack to gain access to 23andMe accounts in October 2023. The San Francisco-based company, which allows people to submit genetic materials and get a snapshot of ...